


Stage IV NSCC: Molecular tests negative (ALK/BRAF/EGFR/ROS1)



LLCG/VZN annotations

1. In patients failing after single agent pembrolizumab, a platinum doublet is the treatment of choice.
2. Nivolumab/ipilimumab is not EMA approved
3. 1st line choice can be chemo-therapy alone if immuno-therapy is contra-indicated. In patients with important comorbidities, single agent chemotherapy or BSC may appropriate.
4. The role of erlotinib in relapsed EGFRwt tumors is doubtful.